Biosimilars are biologic medications that are highly similar to an already approved biologic (called the reference product) but not identical to it. They deliver the same safety, effectiveness, strength, and dosage as the original, and the FDA requires comparative studies to confirm there are no clinically meaningful differences. With over 80 biosimilars now approved in the U.S. and average prices about 50% lower than the original biologics, they represent a real option for reducing treatment costs. Here’s what you should actually understand before you encounter one on a prescription or in a conversation with your doctor.
Biosimilars Are Similar, Not Generic
Unlike traditional generic drugs, which are chemically identical copies of small-molecule medications, biosimilars are made from living cells or microorganisms. That biological manufacturing process means no two batches of any biologic, including the original, are ever perfectly identical. Minor batch-to-batch variation is normal even within the same brand-name product. A biosimilar goes through this same reality: it’s made from the same types of living sources, treats the same conditions, and is given the same way, but its molecular structure won’t be a perfect mirror of the original.
This distinction matters because it shapes how biosimilars are tested and approved. Instead of simply proving chemical equivalence the way a generic pill would, biosimilar manufacturers must provide extensive analytical, structural, and functional comparisons against the reference product. They then run clinical studies comparing how the two drugs behave in the body and whether the biosimilar triggers any different immune responses. The bar is high: the FDA requires evidence that there are no meaningful differences in safety or effectiveness.
Switching From an Original Biologic Is Safe
If your doctor suggests moving you from a brand-name biologic to a biosimilar, the clinical evidence is reassuring. A large systematic review and meta-analysis that pooled data across multiple switching studies found no difference in deaths, serious adverse events, or rates of treatment discontinuation between patients who switched and those who stayed on their original medication. The risk difference across all those safety outcomes was essentially zero.
Immune-related concerns are often the biggest worry with biologics, since these drugs can sometimes trigger the body to produce antibodies against them. The same review found that rates of anti-drug antibodies, neutralizing antibodies, anaphylaxis, hypersensitivity reactions, and injection-site reactions were all similar in switched and non-switched patients. In short, switching does not appear to introduce new immune risks.
Interchangeability and Pharmacy Substitution
Not every biosimilar can be swapped in at the pharmacy without your doctor’s involvement. The FDA distinguishes between a standard biosimilar and an “interchangeable” biosimilar. Both meet the same high standard of safety and effectiveness. The difference is practical: an interchangeable biosimilar can, depending on your state’s laws, be substituted by a pharmacist the same way a generic drug might be, without requiring a new prescription from your doctor.
Thirteen biosimilars have received interchangeable status so far. Notably, the FDA has been relaxing its requirements for that designation. Nine of those 13 were approved as interchangeable without needing additional clinical switching studies, and the agency is moving toward making such studies generally unnecessary. This reflects growing confidence that biosimilars as a class perform reliably when patients switch.
In Europe, the regulatory approach differs slightly. The European Medicines Agency considers all approved biosimilars scientifically interchangeable with their reference products. However, individual EU countries still decide whether pharmacists can automatically substitute at the dispensing level.
How to Identify a Biosimilar by Name
Biosimilar names follow a specific pattern that’s worth recognizing on your prescription label. Each one uses the same core drug name as the original biologic, followed by a hyphen and a unique four-letter suffix that has no inherent meaning. For example, you might see “filgrastim-laha” rather than just “filgrastim.” The shared core name tells you the drug is related to the original, and the suffix distinguishes it for tracking and safety monitoring purposes.
This system exists to help pharmacists and doctors accurately identify exactly which product you received, which is important for reporting side effects. It also helps prevent accidental substitution of a biosimilar that hasn’t been designated as interchangeable. If you ever see an unfamiliar suffix on your medication, that’s the naming convention at work.
The Cost Advantage Is Real but Underused
Biosimilars typically launch at prices around 50% lower than the original biologic’s price at the time of their entry to market. For patients on expensive biologics for conditions like cancer, autoimmune diseases, or eye conditions, that can translate to significant savings on copays and out-of-pocket costs.
Despite this, biosimilar market share in the U.S. remains below 20%. Several factors contribute to the gap. One is simple unfamiliarity: patients and some providers aren’t yet comfortable with the concept. Another is structural. Under Medicare Part B, biologics administered in clinics or hospitals are reimbursed based on the average sales price plus a percentage add-on fee. Because that add-on is calculated as a percentage of the original biologic’s price, prescribing a cheaper biosimilar doesn’t always translate into higher reimbursement for the provider. The Inflation Reduction Act of 2022 tried to address this by temporarily bumping the biosimilar add-on from 6% to 8% of the originator’s price, creating a modest financial incentive for clinicians to choose the lower-cost option.
What This Means for Your Treatment
If you’re currently on a biologic or being prescribed one for the first time, a biosimilar may come up as an option. The key things to keep in mind are straightforward: biosimilars go through rigorous comparative testing before approval, switching between a reference biologic and its biosimilar does not increase your risk of side effects or immune reactions, and the cost savings can be substantial. Over 80 biosimilars are now approved in the U.S., covering treatments for cancer, inflammatory conditions, osteoporosis, eye diseases, and more.
Your insurance plan may prefer or require a biosimilar, or your doctor may recommend one to lower your costs. In either case, the clinical evidence supports the safety of that choice. The four-letter suffix on your prescription label simply identifies which manufacturer’s version you’re receiving, not a meaningful difference in what the drug does.